Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US reimbursement for TAVI is boost for Edwards but market may remain tough

This article was originally published in Clinica

Executive Summary

Edwards Lifesciences' Sapien transcatheter heart valve is to be reimbursed in the US in patients with severe symptomatic aortic stenosis unable to undergo open heart surgery. Edwards' share price on the New York Stock Exchange closed up 2% at $84.78 on 1 May when the decision by the US Centers for Medicare and Medicaid Services (CMS) was announced.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT098851

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel